Health and wellness company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of the final approval from the US Food and Drug Administration (FDA) for its AB rated Abbreviated New Drug Application referencing Zovirax Cream, 5% (acyclovir cream, 5%) against herpes viruses.
The company added the generic Zovirax Cream, 5% (acyclovir cream, 5%) was developed in collaboration with Sol-Gel Technologies Ltd (NASDAQ:SLGL).
Following the US FDA's approval, the company anticipates launching Zovirax Cream, 5% (acyclovir cream, 5%) this month.
For the 12 months ending December 2018, the annual market sales were approximately USD92m as measured by IQVIA, concluded the company
Perrigo awarded US FDA's final approval for AB Rated generic Zovirax Cream 5%
Mylan wins US FDA approval for Wixela Inhub for treating asthma & COPD patients
The US Food and Drug Administration approves first generic Advair Diskus for COPD
FDA Approves Dr. Reddy's Tosymra 10 mg, in the US Market
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
Amerigen awarded US FDA's approval for generic mixed amphetamine salts, extended-release capsules
Amneal wins US FDA approval for Rivastigmine Transdermal System
Premier Expands Effort to Supply Shortage Generic Drugs
Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
China's Bio-Thera Solutions Partners with Cipla to Market Key Cancer Biosimilar
EpicGenetics Moves into New Facility, Expanding Capacity by 4X